AMSTERDAM, The Netherlands, March 22, 2018 (GLOBE NEWSWIRE) — Wright Medical Group N.V. (NASDAQ:WMGI) today announced that it will highlight new innovations at the American College of Foot and Ankle Surgeons (ACFAS) 2018 Scientific Conference taking place at the Gaylord Opryland Hotel in Nashville, Tennessee, from March 22-25, 2018.
Wright will feature its full range of lower extremities and biologic solutions at exhibit booth #244, including the INVISION™ Total Ankle Revision System with PROPHECY Preoperative Navigation, the first preoperative planning system with patient-specific instrumentation for ankle revision arthroplasty. The introduction of INVISION with PROPHECY is an important addition to Wright’s total ankle portfolio, extending the use of preoperative planning to the entire continuum of care from primary through revision procedures.
“The INVISION Total Ankle Revision System with PROPHECY Preoperative Navigation builds on Wright Medical’s commitment to providing physicians with innovative tools that lead to the best possible patient outcomes,” said Robert Palmisano, President and Chief Executive Officer of Wright. “Total ankle arthroplasties provide a unique set of challenges for our physicians and we are excited to be bringing this technology to market to see its success in action. The launch of INVISION with PROPHECY expands our leadership in total ankle technology and marks our ability to best address the total ankle replacement continuum of care.”
The PROPHECY System was first approved for total ankle replacement in 2012 and has been clinically proven to help surgeons accurately align ankle replacements1 and increase surgical efficiency by reducing OR time and potentially cost2. Developed from the patient’s own CT scan, implant sizing and alignment are determined using the patient’s unobstructed anatomic landmarks and the surgeon’s preferences. PROPHECY alignment guides are subsequently created, providing patient-specific instruments to help the surgeon precisely position implants while reducing surgical steps, which in turn allows for less procedural complexity and surgery time.
“Revision of a failed total ankle arthroplasty remains a challenge,” said Dr. William McGarvey, Chief of Foot and Ankle Surgery at the McGovern Medical School at the University of Texas Health Science Center – Houston, who has performed several revision procedures with PROPHECY to date. “The ability to preoperatively plan out these cases and determine appropriate alignment based on the individual patient’s CT data will provide surgeons with an extra level of confidence that the implants will be positioned in the optimal alignment.”
Key benefits of PROPHECY now include:
- Full array of implant choices (INFINITY™, INBONE™ or INVISION™) to fit the patient’s specific needs
- Ability to create a detailed revision surgical plan with or without failed implants currently in place
- 3D visualization of how to manage bone loss and reconstruct joint height under unique revision conditions
Recent new products to be featured at ACFAS include:
INVISION™ Total Ankle Revision System – The first and only system developed specifically for total ankle revision arthroplasty, the INVISION Total Ankle Revision System provides a unique solution for even the most difficult revision procedures. Whether leveraged as a standalone construct or in conjunction with INFINITY and INBONE components, the INVISION Total Ankle Revision System is an important addition to the continuum of care from total ankle replacement through any necessary revisions. The INVISION Total Ankle Revision System helps surgeons re-build bone lost through previous surgeries and provides modularity to help restore natural joint height.
ORTHOLOC™ 3Di Ankle Fracture Low Profile System – The ORTHOLOC 3Di Ankle Fracture Low Profile System features a complete range of ankle fracture plates designed specifically for the foot and ankle surgeon. The system features low-profile, anatomic plate designs and ORTHOLOC 3Di polyaxial locking screw technology, providing an innovative fracture solution that addresses a primary need for one of the foot and ankle’s largest market segments.
For more information about Wright Medical’s portfolio of total ankle products, visit: www.totalankleinstitute.com
1 Hsu AR, Davis WH, Cohen BE, Jones CP, Ellington JK, Anderson RB. Radiographic outcomes of preoperative CT scan-device patient-specific total ankle arthroplasty. Foot Ankle Int 2015;36:1163-1169.
2 Hamid KS, Matson AP, Nwachukwu BU, Scott DJ, Mather RC, DeOrio JK. Determining the cost-savings threshold and alignment accuracy of patient-specific instrumentation in total ankle replacements. Foot Ankle Int 2016;38:49-57.
Internet Posting of Information
Wright routinely posts information that may be important to investors in the “Investor Relations” section of its website at www.wright.com. The company encourages investors and potential investors to consult the Wright website regularly for important information about Wright.
About Wright Medical Group N.V.
Wright Medical Group N.V. is a global medical device company focused on extremities and biologics products. The company is committed to delivering innovative, value-added solutions improving quality of life for patients worldwide and is a recognized leader of surgical solutions for the upper extremity (shoulder, elbow, wrist and hand), lower extremity (foot and ankle) and biologics markets, three of the fastest growing segments in orthopedics. For more information about Wright, visit www.wright.com.
Cautionary Note Regarding Forward-Looking Statements
This release includes forward-looking statements under the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “intend,” “could,” “may,” “will,” “believe,” “estimate,” “look forward,” “forecast,” “goal,” “target,” “project,” “continue,” “outlook,” “guidance,” “future,” other words of similar meaning and the use of future dates. Forward-looking statements in this release include, but are not limited to, statements about the performance and market acceptance of the company’s products. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Each forward-looking statement contained in this release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, physician acceptance, endorsement, and use of company products; the effect of regulatory actions, changes in and adoption of reimbursement rates; product liability claims; product recalls; the effects of industry, economic or political conditions outside of the company’s control; competitor activities; and the risks identified under the heading “Risk Factors” in Wright’s Annual Report on Form 10-K for the year ended December 31, 2017 filed by Wright with the SEC on February 28, 2018 and in other subsequent SEC filings by Wright. Investors should not place considerable reliance on the forward-looking statements contained in this release. Investors are encouraged to read Wright’s filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this release speak only as of the date of this release, and Wright undertakes no obligation to update or revise any of these statements. Wright’s business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.
Investors & Media:
Julie D. Tracy
Sr. Vice President, Chief Communications Officer
Wright Medical Group N.V.